Published clinical guidelines from organizations including the American Society of Metabolic and Bariatric Surgery and the Obesity Medicine Association have identified GLP-1 receptor agonists as appropriate pharmacological interventions in patients with a BMI of 30 or above (classified as obesity), or BMI of 27 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea - the same criteria framework used by the FDA in evaluating GLP-1 medications for their obesity management indications
The doses of GLP-1 agonist used in these studies ranged from 0.01 mg twice daily up to 3 mg daily
This ensures a steady and sustainable weight loss pace
To view a copy of this license, visit About this article Cite this article Nowell, J., Blunt, E
It also includes eating enough to fuel your workouts instead of constantly undercutting your energy
Thats according to the study funded by Lilly, which was published Sunday in the New England Journal of Medicine